Wolf Picks – Sports Betting Insights and Analysis

A parlay bet is a popular form of sports wagering most gamblers are familiar with. In case youre not, this bet is rather easy to understand. A parlay is simply a combo bet where, rather than betting several teams individually, you group them into a single wager. Using this option, the payout is greater and the risk is less, but you need all teams selected to win.

What happens if theres a push in a parlay? That bet will be taken out of the parlay and the payout will be reduced as if there were one fewer team in the parlay. So if you had a 4 team parlay and you got three picks cocrrect and the other was a push, you would be paid out the odds of a 3 team parlay.

Most common sense parlays by Wolf picks

Reduced Juice BetOnline.ag offers 6.5 to one on three team parlays. This comes out better than betting sides at the -105 price standard reduced juice sports books offer. In sports such as NFL football where 50/50 wagering propositions are common, a sports bettor gets far superior odds by betting 3 team parlays at BetOnline.

Free Play Bonuses Several online betting sites, for example Bookmaker.eu, offer players free bets based on the size of their initial deposit. Free play bonuses are not the same as cash. The difference is that a bet made with cash returns both stake and win, where a bet made with a free play returns only win. Parlays allow you the chance to use the same free play more than once, because a parlay really is only a wager that continues to place stake+win on the next selection. Remember, fixed odd three team parlays pay a little better than true odds. So when using free plays to bet 3 team parlays, youre getting slightly better odds, and also a chance to apply that free play stake to three different bets. This is common knowledge that 3 team parlays are a great use of free play bonuses.

Online the odds are similar, though some sites such as 5Dimes and BetOnline offer better odds starting with three teams and up. Whats important to note is that these are fixed odds based on a 50/50 wagering proposition. If a spread is listed at Home Team -7 / Road Team +7 this is 50/50 proposition. If, instead, the spread was Home Team -7 -105 / Road Team +7 -115, this is no longer a 50/50 proposition, and the payout will be calculated using a method bookmakers refer to as true odds. Lets take a moment to understand where fixed parlay odds are derived from.

I mean, when you 5-8 nba predictions, picks and parlays a day youre stretched very thin. And your return and ability to scale is low. And then when the nba season finisheswhat about other sports like MLB, NFL, college football and even college basketball. All of this compliments nba predictions picks and parlays.

This enables us to drill down to and provide the best nba predictions, picks and parlays. It works for mlb, nfl, college basketball and college football and soccer. We analyse 50+ games a week and narrow it down to a 2 team parlay.

Every 12 weeks, we open up our doors to a few more people. You will be placed in a 12 week trial membership. The cost is $10/wk (and remember if the picks/parlays lose you get an instant refund). DO NOT wager more than $10/game for the first 12 weeks. This is just a trial to build your trust and confidence. After the 12 weeks is up, and you have won 7-9 if the 12weeks, you will be given the chance to join the main group and secure your seat at the table. The cost will be $30/wk and the refund guarantee still applies. More informations at https://sites.google.com/site/nbapredictionspicksandpaam9/

Hong Kong Regenerative Medisun Association launched by Medisun

Medisun launched the “Hong Kong Regenerative Medisun Association”

On May 28, 2018, the Hong Kong Regenerative Medisun Association, which was initiated by representatives from the Hong Kong Regenerative Medisun Industry and academic circles, was formally established under the auspices of the Medisun Medical Group.

Hong Kong Regenerative Medisun Association goals

The Hong Kong Regenerative Medisun Association was founded by experts, scholars, industry representatives and people of insight in the field of regenerative Medisun in Hong Kong and around the world. The purpose of the association is to establish a consensus platform for the regenerative Medisun industry in Hong Kong, promote the development of the regenerative Medisun industry, encourage and promote international cooperation, and propose to the Hong Kong SAR government the recommendations of the regenerative Medisun industry on industry regulations and actively influence industry rules. The establishment and improvement of the company provides effective technical and management advice to the Hong Kong government, Hong Kong public health agencies and companies in the industry.

The first meeting of the Hong Kong Regenerative Medisun Association (May 28, 2018)

On the afternoon of May 28, representatives from Hong Kong’s medical health, regenerative Medisun and biotechnology fields, doctors, pharmacists, chemists and university researchers gathered to discuss and elect the first council of the Hong Kong Regenerative Medisun Association.They read the charter of the association and clarify the duties of the board. At the same time, they have had a heated discussion on the regulatory documents issued by the Hong Kong SAR Government on Advanced Therapy Products. They agreed to regulate the direction of document guidance and proposed a number of issues that need to be clarified, including:

1. Professional qualifications required by the licensee of the Regenerative Medisun and Stem Cell Research and Development Organization;

2. Advanced Therapy Products is regulated by the Pharmacy and Poisons Ordinance (Cap. 138). However, since the production process and user definition of cellular products and pharmaceutical products are different, they should be clarified accordingly;

3. With reference to the requirements of the international GMP/PICS standard, which standard should be achieved in the cell laboratory qualification of existing regenerative Medisun institutions;

4. After the specific regulation is in force, whether there should be a transition period, so that the industry has time to adjust and cooperate;

5. Submit the Advanced Therapy Products comments and submit them to the Hong Kong Department of Health.

Member of the First Council of the Hong Kong Regenerative Medisun Association

Position

Name

 Qualifications

Chairman

Danny Wong Mr. Wang Xiaofeng

 Founder and Chairman of Medisun Medical Group, years of investment experience in the field of regenerative Medisun, understanding the development and trends of the biotechnology industry

Vice President

Joseph Wang  Dr. Wang Qiyuan

Registered as a doctor, founder of the Hong Kong Stem Cell Center, enriching the clinical experience of regenerative Medisun

Vice President

David Leung Mr. Liang Yaoming

Registered pharmacist, familiar with pharmaceutical regulations and GMP requirements

Vice Chairman

Gregory Cheng Professor Zheng Yanming

Hematology expert, Professor of the University of Macau Health Sciences

Director | Treasurer

Kenneth Lee Dr. Li Zhisheng

Registered as a doctor, B Q Anti-aging Center Consultant

Director

Philip Choy Dr. Cai Shaolong

Ph.D. in Natural Medisun, Madison Biomedical Director

Director

Daniel Tam Dr. Tan Yizhu

Registered as a medical laboratory technologist, director of the Trans-Olympic Blood Bank Laboratory, focusing on cell culture technology for many years

Director

Vivien Leung Ms. Liang Yiqun

 Registered as a medical laboratory technologist, manager of the Trans-Olympic Blood Bank Laboratory, familiar with quality management

Director

Chris Wong Dr. Huang Libao

 Registered as a medical laboratory technologist, director of HKMDPC, molecular biodiagnostic expert

Secretary

Sidney Tam Dr. Tan Guozhen

Chief Executive Officer, Life Clinic, Health Management Consultant

Secretary

Allen Chan Mr. Chen Yuxin

Registered as a medical laboratory technologist, familiar with quality management

The first meeting of the Hong Kong Regenerative Medisun Association (May 28, 2018)

Hong Kong Regenerative Medisun Association’s recent work plan

Next, the Hong Kong Regenerative Medisun Association will issue letters to the organizations including the Hong Kong Department of Health, the Hong Kong Stock Exchange, the Hong Kong University Biomedical Science, Life Sciences, and the Global Regenerative Medisun Alliance (ARM). include:

1. Announced the official establishment of the Hong Kong Regenerative Medisun Association

2. Announce the initial membership list of the Hong Kong Regenerative Medisun Council, association charter, association vision and goals

3. Call for the support and participation of experts, scholars and industry representatives from Hong Kong and around the world

4. Propose to the Hong Kong Government to clarify regulatory regulations on Advanced Medisun and Advanced Therapy Products

Special thanks

Thank you for taking the time to attend the representatives of the institutions, including:

Medisun Medical Group | Medisun Reproductive Medisun Center

Hong Kong Life Science and Technology Group Co., Ltd.

Standard Pathology Laboratory Co., Ltd.

BIH

Living Tissues company limited

BIB Health Care Centre

Hongxin Medical Center

Austa beauty

Hong Kong International Regenerative Medisun Centre

HKMPDC

Huixin Technology

Guangzhou Biological Institute

Trans-along cord blood bank

Hong Kong Stem Cell Center

Life Length

Biocell

Cordlife

For more information, please visit http://www.medisun.hk/

Hong Kong Regenerative Medisun Association launched by Medisun

Medisun launched the “Hong Kong Regenerative Medisun Association”

On May 28, 2018, the Hong Kong Regenerative Medisun Association, which was initiated by representatives from the Hong Kong Regenerative Medisun Industry and academic circles, was formally established under the auspices of the Medisun Medical Group.

Hong Kong Regenerative Medisun Association goals

The Hong Kong Regenerative Medisun Association was founded by experts, scholars, industry representatives and people of insight in the field of regenerative Medisun in Hong Kong and around the world. The purpose of the association is to establish a consensus platform for the regenerative Medisun industry in Hong Kong, promote the development of the regenerative Medisun industry, encourage and promote international cooperation, and propose to the Hong Kong SAR government the recommendations of the regenerative Medisun industry on industry regulations and actively influence industry rules. The establishment and improvement of the company provides effective technical and management advice to the Hong Kong government, Hong Kong public health agencies and companies in the industry.

The first meeting of the Hong Kong Regenerative Medisun Association (May 28, 2018)

On the afternoon of May 28, representatives from Hong Kong’s medical health, regenerative Medisun and biotechnology fields, doctors, pharmacists, chemists and university researchers gathered to discuss and elect the first council of the Hong Kong Regenerative Medisun Association.They read the charter of the association and clarify the duties of the board. At the same time, they have had a heated discussion on the regulatory documents issued by the Hong Kong SAR Government on Advanced Therapy Products. They agreed to regulate the direction of document guidance and proposed a number of issues that need to be clarified, including:

1. Professional qualifications required by the licensee of the Regenerative Medisun and Stem Cell Research and Development Organization;

2. Advanced Therapy Products is regulated by the Pharmacy and Poisons Ordinance (Cap. 138). However, since the production process and user definition of cellular products and pharmaceutical products are different, they should be clarified accordingly;

3. With reference to the requirements of the international GMP/PICS standard, which standard should be achieved in the cell laboratory qualification of existing regenerative Medisun institutions;

4. After the specific regulation is in force, whether there should be a transition period, so that the industry has time to adjust and cooperate;

5. Submit the Advanced Therapy Products comments and submit them to the Hong Kong Department of Health.

Member of the First Council of the Hong Kong Regenerative Medisun Association

Position

Name

 Qualifications

Chairman

Danny Wong Mr. Wang Xiaofeng

 Founder and Chairman of Medisun Medical Group, years of investment experience in the field of regenerative Medisun, understanding the development and trends of the biotechnology industry

Vice President

Joseph Wang  Dr. Wang Qiyuan

Registered as a doctor, founder of the Hong Kong Stem Cell Center, enriching the clinical experience of regenerative Medisun

Vice President

David Leung Mr. Liang Yaoming

Registered pharmacist, familiar with pharmaceutical regulations and GMP requirements

Vice Chairman

Gregory Cheng Professor Zheng Yanming

Hematology expert, Professor of the University of Macau Health Sciences

Director | Treasurer

Kenneth Lee Dr. Li Zhisheng

Registered as a doctor, B Q Anti-aging Center Consultant

Director

Philip Choy Dr. Cai Shaolong

Ph.D. in Natural Medisun, Madison Biomedical Director

Director

Daniel Tam Dr. Tan Yizhu

Registered as a medical laboratory technologist, director of the Trans-Olympic Blood Bank Laboratory, focusing on cell culture technology for many years

Director

Vivien Leung Ms. Liang Yiqun

 Registered as a medical laboratory technologist, manager of the Trans-Olympic Blood Bank Laboratory, familiar with quality management

Director

Chris Wong Dr. Huang Libao

 Registered as a medical laboratory technologist, director of HKMDPC, molecular biodiagnostic expert

Secretary

Sidney Tam Dr. Tan Guozhen

Chief Executive Officer, Life Clinic, Health Management Consultant

Secretary

Allen Chan Mr. Chen Yuxin

Registered as a medical laboratory technologist, familiar with quality management

The first meeting of the Hong Kong Regenerative Medisun Association (May 28, 2018)

Hong Kong Regenerative Medisun Association’s recent work plan

Next, the Hong Kong Regenerative Medisun Association will issue letters to the organizations including the Hong Kong Department of Health, the Hong Kong Stock Exchange, the Hong Kong University Biomedical Science, Life Sciences, and the Global Regenerative Medisun Alliance (ARM). include:

1. Announced the official establishment of the Hong Kong Regenerative Medisun Association

2. Announce the initial membership list of the Hong Kong Regenerative Medisun Council, association charter, association vision and goals

3. Call for the support and participation of experts, scholars and industry representatives from Hong Kong and around the world

4. Propose to the Hong Kong Government to clarify regulatory regulations on Advanced Medisun and Advanced Therapy Products

Special thanks

Thank you for taking the time to attend the representatives of the institutions, including:

Medisun Medical Group | Medisun Reproductive Medisun Center

Hong Kong Life Science and Technology Group Co., Ltd.

Standard Pathology Laboratory Co., Ltd.

BIH

Living Tissues company limited

BIB Health Care Centre

Hongxin Medical Center

Austa beauty

Hong Kong International Regenerative Medisun Centre

HKMPDC

Huixin Technology

Guangzhou Biological Institute

Trans-along cord blood bank

Hong Kong Stem Cell Center

Life Length

Biocell

Cordlife

For more information, please visit http://www.medisun.hk/

Dubai Property Investments: A Good Bargain

Freehold properties in Dubai are, for the most part, still incredible good value for money. First of all buying property in Dubai is a 100% tax free experience, something you will not find many places in the world. As an investor you will not be taxed on your capital gains or the rental income you get from your tenants. This is of course equally important for those who are looking to buy a holiday home. The owners can subsidize their household budget with a tax free rental income. FazWaz UAE can help you in your property investments in Dubai and UAE. Continue reading “Dubai Property Investments: A Good Bargain”

spiritual British Isles Tours

Body and Minds Spirit Journeys presents : Three British Isles Tours for you to choose

Scotland, England and Ireland are rich with some of the most magical places of Mother Earth. Now, Body Mind Spirit Journeys invites you to experience three sacred sites tours next Spring.

England and Cornwall: May 23 June 1, 2018

Tarot Magic in Merlins Britain is your chance to feel the energy of sacred sites and landscapes by following in the footsteps of King Arthur, his powerful wizard Merlin, and Morgan La Fey.

– Listen for whispered messages in Merlins Cave at Tintagel, at Stonehenge, on the ancient Isle of Avalon (Glastonbury) and at Avebury.
– Visit the giant hill fort of Cadbury/Camelot
– Take part in a Druid sunrise ceremony inside the circle of Stonehenge
– Through Tarot readings in sacred sites and workshops with renowned Tarot expert Mary Greer, gain insight into your own spiritual journey

See the England & Cornwall tour details here.

BMSJ can arrange that opportunity for you and assist with every detail.

Dalai LamaWith over 25 years as innovators in the field of sacred and wellness travel, we lead the industry in working with leaders who can bring a group of people together for a common cause and/or travel experience. The only question is, where would you like to go? Many tour hosts with large followings actually earn revenue with their travel programs. Others, hosting the occasional tour, are able to travel free or at a discounted rate, simply by inviting their friends and contacts to travel with them. Whether your group is large or small, BMSJ is happy to walk you through the process and assist you with every step of the way.

More spiritual England and Cornwall Tours info :

Body Mind Spirit Journeys
P.O. Box 448
Montauk, NY 11954
USA
BMSJ@bodymindspiritjourneys.com

Body Mind Spirit Journeys is a division of RMC Travel.

The famous American vaccine company Profectus settled in Hong Kong

The famous American vaccine company Profectus settled in Hong Kong

First recommend HPV cervical cancer treatment vaccine

BALTIMORE, MARYLAND, USA and HONG KONG, April 20, 2018

Profectus Biotech and Medisun Medical Group today announced the opening of a new joint venture in Hong Kong. The primary mission of the new company, ProMed BioSciences, Ltd., is to establish a leading vaccine company focused on the development of preventive and therapeutic vaccines for infectious diseases and cancer. The joint venture will leverage Profectus’ vaccine development expertise, clinically proven vaccine platform technology and a developing vaccine product line, in line with Medisun’s expertise, established clinical network and market access capabilities, expected in the second half of 2018 to put into operation.

The company’s first product development program will focus on the development, production and commercial application of prophylactic and therapeutic vaccines for HPV (human papillomavirus)-related lesions and cervical cancer [based on PBSVax® technology developed by Profectus]. ProMed BioSciences also plans to develop and treat hepatitis C virus (HCV), hepatitis B virus (HBV), herpes simplex virus (HSV), respiratory syncytial virus (RSV), and human immunodeficiency virus (HIV). Chikungunya and Zika, as well as personalized vaccines to treat cancer. The joint venture is expected to launch new vaccines in their respective markets, which will help promote the development of new vaccines, but ultimately the goal is to benefit patients around the world.

Mr. Jeffery Meshulam (first from left), President of Profectus Biotechnology, Mr. Terry Lierman (second from left), Chairman of Medivh Medical Group, and Mr. Danny Wong (fourth from right), founder and executive chairman of Medisun Medical Group, at Profectus ,USA.

– Long-term strategic cooperation to address the huge demand for prevention and treatment of infectious diseases and cancer in Asia

-Profectus’ expertise in vaccine development and platform technology, combined with Medisun’s localized expertise and experience, to establish a leading Hong Kong vaccine company focused on serving Asia

“This strategic cooperation will help establish Profectus’ business in Hong Kong and China. Through close cooperation with Medisun, we can assist Hong Kong and China to develop advanced vaccine technology to help prevent and treat Asian patients. Mr. Jeffrey Meshulam, President of Profectus, said, “We are pleased to be able to work with recognized local partners to achieve the highest standards of scientific research and development integration and medical services.”

“This collaboration will help Profectus and Medisun to jointly produce life-saving vaccines for infectious diseases and cancer, and address the huge medical needs that have not been met in Hong Kong, China and Asia.” Mr. Danny Wong, founder and executive chairman of Medisun Medical Group, said “ProMed BioSciences will leverage Profectus’ expertise in vaccine development and technology, combined with Medisun’s local expertise and close links with healthcare facilities in Hong Kong and China, and government medical regulatory agencies to develop vaccines to provide leadership for Asian patients disease prevention and treatment programs.”

ProMed BioSciences will focus on the following:

• Conduct technical research in Hong Kong or China

• Conduct clinical trials in Hong Kong or China

• Promote the expansion of Medisun Medical Center

• Develop vaccines to address disease prevention needs

• leverage to maximize the expertise of both partners

Mr. Jeffery Meshulam, President of Profectus Biotechnology (first from left), Mr. Terry Lierman, Chairman of Medisun Medical Group (first from right), Mr. Danny Wong, founder and executive chairman of Medisun Medical Group (middle), at the US headquarters of  Profectus.

About ProMed BioSciences

ProMed BioSciences Limited is a joint venture between Profectus BioSciences (USA) and Medisun Medical Group (Hong Kong) in Hong Kong to develop and conduct new vaccine clinical trials and commercial applications to address infectious diseases and cancer in Asia with the huge demand for prevention and treatment.

About Medisun

Headquartered in Hong Kong, Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative Medisunne products, as well as quality hospitals and treatment centers. Medisun invests extensively in the fields of regenerative and stem cell patent technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, nervous system disease, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun and Harvard University Stem Cell Research Institute, Johns Hopkins Medical School Life Science Center, Tsinghua University and other institutions have long-term cooperation plans to jointly invest in regenerative and stem cell therapy technology, with Medisun as a cooperative business The holding entity and holds global intellectual property rights. Medisun and the University of Maryland’s Institute of Human Virology (IHV) set up a technology clinical trial and development platform for viruses and cancer. Based on the Medisun Biomedical Laboratory in Hong Kong, Radiation will jointly build medical clinics in China and Asia. The experimental resource network promotes the world’s largest clinical research and development platform for virus research and cancer treatment technology. The Medisun Reproductive Centre is located at the Proud Square in Kowloon Bay, Hong Kong. It has a 50,000 square foot stem cell GMP production base, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to develop a rigorous and professional R&D process. Provides immune cell therapy and a variety of stem cell health treatments.

For more information, please visit http://www.medisun.hk/

About Profectus BioSciences

Profectus BioSciences is a clinical stage vaccine development company focused on developing new vaccines for infectious disease and cancer prevention and treatment. The Profectus vaccine is based primarily on the company’s proprietary VesiculoVax™ and DNA vaccine technology platform. By simply using the VesiculoVax™ vaccine alone, B cells can be rapidly expanded to provide protection against emerging infectious diseases that threaten public health and biodefense mechanisms, such as Ebola, Marburg, Chikungunya, Zika virus, equine encephalitis virus, and respiratory syncytial virus. When VesiculoVax™ is used as a vaccine when the immune system is launched with the best pDNA vaccine, the Vesiculo Vax™-directed vaccine expands the triggered T cells into effector cells, which are ideal for attacking virus-infected cells and cancer. Current projects using the Prime / Boost Vaccine System (PBS Vax™) strategy include hepatitis B virus (HBV), human papillomavirus (HPV), herpes simplex virus type 2 (HSV-2) and human immunodeficiency virus ( HIV). Partners and collaborators include UTMB’s Galveston National Laboratory, Yale University, University of Maryland Human Virology Institute, HIV/AIDS Vaccine Immunology Center, National Cancer Institute, National Institutes of Health AIDS Division, Bill And the Melinda Gates Foundation, the International AIDS Vaccine Initiative, the AIDS Vaccine Trial Network and the AIDS Clinical Trial Group. Profectus is funded by Cross Atlantic Capital Partners (“XACP”) in Radnor, Pennsylvania. The main investor in XACP is the Pennsylvania Public School Employees Retirement System (“PSERS”). For more information, please visit www.profectusbiosciences.com